{"entity":{"id":"imc-002","kind":"drug","name":"IMC-002","aka":[],"tldr":"IMC-002 is an experimental monoclonal antibody from ImmuneOncia Therapeutics, in phase 1 trials for advanced solid tumours and lymphoma.","summary":"IMC-002 is a monoclonal antibody (fully human IgG1) from ImmuneOncia Therapeutics. An anti-CD47 antibody that blocks CD47 binding to SIRP-alpha so macrophages engulf cancer cells; the company says its affinity is tuned to avoid binding red blood cells. Its furthest stage is phase 1, for advanced solid tumours and lymphoma. ClinicalTrials.gov registers it in 2 studies linked below. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"ImmuneOncia Therapeutics: immuneoncia.com","url":"https://www.immuneoncia.com/en/m25.php"},{"label":"ImmuneOncia Therapeutics: immuneoncia.com","url":"https://www.immuneoncia.com/en/m23.php"},{"label":"ClinicalTrials.gov: trials of IMC-002","url":"https://clinicaltrials.gov/search?intr=IMC-002"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["cd47"],"drugs":[],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04306224","nct05276310"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"IMC-002","modality":"Monoclonal antibody (fully human IgG1)","mechanism":"An anti-CD47 antibody that blocks CD47 binding to SIRP-alpha so macrophages engulf cancer cells; the company says its affinity is tuned to avoid binding red blood cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/imc-002/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"target":[{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}],"trial":[{"id":"nct05276310","kind":"trial","name":"A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy","route":"/trials/nct05276310/"},{"id":"nct04306224","kind":"trial","name":"A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas","route":"/trials/nct04306224/"}]}}